Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients
Published Online: Thursday, January 16, 2014
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
Hospitalization rates for heart disease and stroke have dropped significantly over the past decade.
Galleon Pharmaceuticals Corp's GAL-021 reverses and prevents respiratory depression associated with opioid use without affecting analgesia.